Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06920004 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Study acronym: emvigorate
StatusRecruiting
PhasePhase 3
Sponsorargenx
Started2025-08-22
View on ClinicalTrials.gov ↗

Amendment history

2026-08-25
Study Status, Contacts/Locations v11
Trial sites expanded: 95 → 101 locations
Trial sites expanded: 89 → 95 locations
Trial sites expanded: 82 → 89 locations
2026-07-20
Study Status, Contacts/Locations v10
Trial sites expanded: 75 → 82 locations
2026-06-11
Study Status, Contacts/Locations v9
Study sites73→75
2026-05-07
Study Status, Contacts/Locations v8
Trial sites expanded: 47 → 73 locations
2026-04-17
Study Status, Contacts/Locations v7
Study sites46→47
Show 6 earlier versions
2026-03-04
Study Status, Study Description, Contacts/Locations, References v6
Study sites27→46
2026-02-06
Study Status, Contacts/Locations v5
Study sites10→27
2026-01-07
Study Status, Contacts/Locations v4
Study sites6→10
2025-12-01
Study Status, Contacts/Locations v3
Study sites4→6
2025-11-03
Study Status, Contacts/Locations v2
Study sites1→4
2025-09-18
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-05→2027-09
Completion date2030-05→2030-09
Start dateestimated 2025-05→confirmed 2025-08-22
2025-04-02
Original filing
Argenx
56 trials monitored
See 2 trials at risk
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Trial Details
NCT Number NCT06920004
Lead Sponsor argenx
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 218 participants
Start Date 2025-08-22
Primary Completion 2027-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-24